Using found poetry to explore creativity in the professional lives of English teachers

This is an Accepted Manuscript of an article published by Taylor & Francis in Teachers and Teaching: Theory and Practice on 26/04/2023, available online: https://doi.org/10.1080/13540602.2023.2201422This arts-based research considers creativity in the professional lives of English teachers in a school in England within the context of a progressively performative education system. In addition, it explores how found poetry can represent participants' voices in an illuminating and authentic manner. The teachers who participated in the study were able to scrutinise, reflect and comment upon the content of poems created from the words found in an initial interview transcript. This recursive process supports a credible way of seeing and knowing the teachers’ voices in a representation that gives a deeper understanding of the participants' creative experiences. The construction, interrogation, and presentation of the found poems reveal that the teachers of English believe they have reduced freedom to be creative or to act with agency in their professional lives. The reduced freedom to be creative stems from the normalising practices of working within a culture of performance. The restrictions are both tangible and self-imposed by the participants

Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism - The COSIMO study.

n/

The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients.

BACKGROUND: The Anti-Clot Treatment Scale (ACTS) is a 15-item patient-reported instrument of satisfaction with anticoagulant treatment. It includes a 12-item ACTS Burdens scale and a 3-item ACTS Benefits scale. Its role in clinical trials and other settings should be supported by evidence that it is both clinically meaningful and scientifically sound. The aim of the study was to evaluate the measurement performance of the ACTS (Dutch, Italian, French, German and English language versions) in patients with venous thromboembolism based on traditional psychometric methods. METHODS: ACTS Burdens and Benefits scale data from a large clinical trial (EINSTEIN DVT) involving 1336 people with venous thromboembolism were analysed at both the scale and item level. Five key psychometric properties were examined using traditional psychometric methods: acceptability, scaling assumptions, reliability (including internal consistency reliability, test-retest reproducibility); validity (including known groups and discriminant validity); and responsiveness. These methods of examination underpin the US Food and Drug Administration recommendations for patient-reported outcome instrument evaluation. RESULTS: Overall, the 12-item ACTS Burdens scale and 3-item ACTS Benefits scale met the psychometric criteria evaluated at both item and scale levels, with the exception of some relatively minor issues in the Dutch language version, which were just below reliability criteria (i.e. alpha = 0.72, test-retest intraclass correlation = 0.79). A consistent finding from item-level evaluations of aggregate endorsement frequencies and skewness suggested that response scales may be improved by reducing the number of response options from five to four. CONCLUSIONS: Both the ACTS Burdens and ACTS Benefits scales consistently satisfied traditional reliability and validity criteria across multiple language datasets, supporting it as a clinically useful patient-reported instrument of satisfaction with anticoagulant treatment in clinical trials. TRIAL REGISTRATION NUMBER: NCT00440193

Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results

Abstract Objective To compare the country-specific value sets of the EQ-5D-5L utility index and to evaluate the impact on the interpretation of clinical study results. Six country value sets from Canada, England, Japan, Korea, Netherlands and Uruguay were obtained from literature. In addition, ten crosswalk value sets were downloaded from the EuroQol.org website. Results For each of the 3125 possible health states the difference between the country with the highest index and the country with the lowest index was calculated. The median difference was 0.417 across the health states. When analyzing multinational clinical studies, country-specific value sets should be used to evaluate treatment effects. Additional country-specific analyses are needed

Cost effectiveness of Rivaroxaban versus low molecular weight heparin and vitamin K antagonists for the treatment of deep-vein thrombosis in the Belgian healthcare setting

Objectives: The aim of the present study was to evaluate the cost-effectiveness of rivaroxaban versus current standard of care for the acute treatment of deep-vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) in the Belgian healthcare setting. Background: The mainstay of therapy for venous thromboembolism has been low-molecular-weight heparin (LMWH) for the initial treatment followed by oral vitamin K antagonists (VKAs) for the continued treatment during 3 to 12 months. VKAs are both effective and inexpensive, but require monitoring and carry a risk of bleeding. Rivaroxaban is the first novel oral anticoagulant that received approval for treating VTE, but there are few data on the cost-effectiveness of rivaroxaban versus LMWH/VKA. Methods: A Markov model was designed and populated with: 1) local cost estimates, 2) comparative 2 year clinical data from the EINSTEIN-DVT phase III trial comparing rivaroxaban with LMWH / VKA and 3) data from medical literature. The results are extrapolated to a total time horizon of 40 years. Results: Rivaroxaban was the dominant treatment option for patients requiring three months or six months treatment and cost-effective (€1,905 per QALY) for patients requiring twelve months of therapy. Sensitivity analyses showed these results were robust across a wide range of data input values. Conclusions: The results of the present cost-effectiveness analysis indicate that rivaroxaban provides a dominant or at least a cost-effective treatment alternative to LMWH/VKA for the treatment of DVT and prevention of recurrent DVT and PE in Belgium